TR200103454T2 - Cinsiyet steroidi öncüleri ile kombinasyon halindeki bir selektif östrojen reseptör modülatörünün tıbbi kullanımları. - Google Patents

Cinsiyet steroidi öncüleri ile kombinasyon halindeki bir selektif östrojen reseptör modülatörünün tıbbi kullanımları.

Info

Publication number
TR200103454T2
TR200103454T2 TR2001/03454T TR200103454T TR200103454T2 TR 200103454 T2 TR200103454 T2 TR 200103454T2 TR 2001/03454 T TR2001/03454 T TR 2001/03454T TR 200103454 T TR200103454 T TR 200103454T TR 200103454 T2 TR200103454 T2 TR 200103454T2
Authority
TR
Turkey
Prior art keywords
estrogen receptor
selective estrogen
sex steroid
combination
receptor modulator
Prior art date
Application number
TR2001/03454T
Other languages
English (en)
Inventor
Labrie Fernand
Original Assignee
Endorecherche, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorecherche, Inc. filed Critical Endorecherche, Inc.
Publication of TR200103454T2 publication Critical patent/TR200103454T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Dehidroepiandrosteron, dehidroepiandrosteron sülfat, androst-5-en-3 , 17 -diol ve kendisinden birine in vivo olarak dönüstürülen bilesiklerden olusan gruptan seçilen bir cinsiyet steroidi öncünün bir miktari ve selektif östrojen reseptör modülatörü, bilhassa, genel yapi (I)'e sahip olan bilesiklerin verilmesini içeren, insanlar da dahil olmak üzere, hassas sicak kanli hayvanlardaki arteryoskleroz, hiperlipidemi, hiperkolesterolemi, gögüs kanseri veya osteoporozun tibbi tedavisi ve/veya bunlarin gelisiminin inhibisyonu için yeni metotlar. Selektif östrojen reseptör modülatörleri ve/veya cinsiyet steroidi öncüsü ile kombinasyon halindeki bifosfonatlarin ilave olarak verilmesi; osteoporozun tibbi tedavisi ve/veya bunlarin gelisiminin inhibisyonu için bildirilmektedir. Bulusa faydali aktif muhteviyat ve kitlerin dagitilmasi için farmasötik kompozisyonlar da bildirilmeketedir. (Formül I)
TR2001/03454T 1998-06-11 1999-06-10 Cinsiyet steroidi öncüleri ile kombinasyon halindeki bir selektif östrojen reseptör modülatörünün tıbbi kullanımları. TR200103454T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/096,284 US6465445B1 (en) 1998-06-11 1998-06-11 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Publications (1)

Publication Number Publication Date
TR200103454T2 true TR200103454T2 (tr) 2002-06-21

Family

ID=22256661

Family Applications (5)

Application Number Title Priority Date Filing Date
TR2001/03453T TR200103453T2 (tr) 1998-06-11 1999-06-10 Cinsiyet steroidi öncüleri ile kombinasyon halindeki bir selektif östrojen reseptör modülatörünün tıbbi kullanımları
TR2001/03454T TR200103454T2 (tr) 1998-06-11 1999-06-10 Cinsiyet steroidi öncüleri ile kombinasyon halindeki bir selektif östrojen reseptör modülatörünün tıbbi kullanımları.
TR2001/00551T TR200100551T2 (tr) 1998-06-11 1999-06-10 Cinsiyet steroidi öncüleri ile kombinasyon halindeki bir selektif östrojen reseptör modülatörünün tıbbi kullanımları
TR2001/03455T TR200103455T2 (tr) 1998-06-11 1999-06-10 Cinsiyet steroidi öncüleri ile kombinasyon halindeki bir selektif östrojen reseptör modülatörünün tıbbi kullanımları
TR2001/03456T TR200103456T2 (tr) 1998-06-11 1999-06-10 Cinsiyet steroidi öncüleri ile kombinasyon halindeki bir selektif östrojen reseptör modülatörünün tıbbi kullanımları.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2001/03453T TR200103453T2 (tr) 1998-06-11 1999-06-10 Cinsiyet steroidi öncüleri ile kombinasyon halindeki bir selektif östrojen reseptör modülatörünün tıbbi kullanımları

Family Applications After (3)

Application Number Title Priority Date Filing Date
TR2001/00551T TR200100551T2 (tr) 1998-06-11 1999-06-10 Cinsiyet steroidi öncüleri ile kombinasyon halindeki bir selektif östrojen reseptör modülatörünün tıbbi kullanımları
TR2001/03455T TR200103455T2 (tr) 1998-06-11 1999-06-10 Cinsiyet steroidi öncüleri ile kombinasyon halindeki bir selektif östrojen reseptör modülatörünün tıbbi kullanımları
TR2001/03456T TR200103456T2 (tr) 1998-06-11 1999-06-10 Cinsiyet steroidi öncüleri ile kombinasyon halindeki bir selektif östrojen reseptör modülatörünün tıbbi kullanımları.

Country Status (29)

Country Link
US (6) US6465445B1 (tr)
EP (5) EP1083905B1 (tr)
JP (3) JP2002517433A (tr)
KR (6) KR20090018871A (tr)
CN (2) CN1240388C (tr)
AR (1) AR043075A1 (tr)
AT (1) ATE308326T1 (tr)
AU (1) AU4253099A (tr)
BR (1) BR9911116A (tr)
CA (7) CA2768682C (tr)
CY (4) CY1113712T1 (tr)
DE (1) DE69928104T2 (tr)
DK (5) DK2386304T3 (tr)
ES (5) ES2458218T3 (tr)
HK (1) HK1040367B (tr)
HU (2) HU230495B1 (tr)
ID (1) ID28696A (tr)
IL (3) IL140178A0 (tr)
MX (1) MXPA00012306A (tr)
MY (3) MY125047A (tr)
NO (2) NO331022B1 (tr)
NZ (1) NZ508801A (tr)
PL (4) PL199798B1 (tr)
PT (4) PT2386304E (tr)
RU (1) RU2246947C2 (tr)
TR (5) TR200103453T2 (tr)
TW (2) TWI258369B (tr)
WO (1) WO1999063974A2 (tr)
ZA (1) ZA200007297B (tr)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11513390A (ja) * 1995-10-06 1999-11-16 アーチ デベロップメント コーポレイション 細胞殺傷のウイルス増強のための方法および組成物
US7005428B1 (en) * 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
EP1104414B1 (en) * 1998-08-14 2003-02-12 Schering Corporation Enantioselective synthesis
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
AR021719A1 (es) * 1998-12-18 2002-07-31 Schering Corp Composicion farmaceutica oral antiestrogenica.
US6583129B1 (en) 1999-06-11 2003-06-24 Watson Pharmaceuticals, Inc. Administration of non-oral androgenic steroids to women
CA2376158C (en) 1999-07-06 2011-03-15 Endorecherche, Inc. Use of selective estrogen receptor modulators in the manufacture of medicaments for treating and/or suppressing weight gain
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
BR0108107A (pt) * 2000-01-28 2003-03-11 Endorech Inc Moduladores seletivos dos receptores de estrogênio em combinação com estrogênios; kits e composições farmacêuticas para praticar tal combinação; bem como a administração da referida combinação
AU2001241779A1 (en) 2000-02-25 2001-09-03 Hollis-Eden Pharmaceuticals, Inc. Method of treatment of prostate cancer
AU2001256164A1 (en) * 2000-03-01 2001-09-12 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy
AU7178301A (en) * 2000-07-06 2002-01-21 American Home Prod Methods for increasing nitric oxide synthase activity
AU2001273144A1 (en) * 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
AU2001273125A1 (en) * 2000-07-06 2002-01-21 American Home Products Corporation Combinations of bisphosphonates, estrogenic agents and optionally estrogens
JP2004507465A (ja) 2000-08-11 2004-03-11 ワイス エストロゲン受容体陽性癌腫の治療方法
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
IL145876A0 (en) * 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
FR2827764B1 (fr) * 2001-07-27 2005-08-19 Oreal Composition, notamment cosmetique, renfermant un steroide et un glycol
JP2005504032A (ja) 2001-07-31 2005-02-10 ファイザー・プロダクツ・インク エストロゲン・アゴニスト／アンタゴニスト、エストロゲン及びプロゲスチンの組み合わせを含む医薬組成物、キット及び方法
US20040044226A1 (en) * 2001-10-15 2004-03-04 Dininno Frank P. Estrogen receptor modulators
DK1501819T3 (da) * 2002-04-24 2011-01-10 Merck Sharp & Dohme Østrogenreceptormodulatorer
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
CA2536946A1 (en) * 2003-08-26 2005-03-03 Board Of Regents, The University Of Texas System Estrogen receptor modulators and uses thereof
CA2581316C (en) 2004-09-21 2013-09-10 Novogen Research Pty Ltd Substituted chroman derivatives, medicaments and use in therapy
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
US8941594B2 (en) * 2004-10-01 2015-01-27 Nvidia Corporation Interface, circuit and method for interfacing with an electronic device
US8835413B2 (en) * 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
EP1871433B1 (en) 2005-03-24 2009-04-22 NOLabs AB Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor
RU2297798C1 (ru) * 2005-10-03 2007-04-27 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук ГУ НИИ онкологии ТНЦ СО РАМН Способ комплексного лечения резектабельных форм рака эндометрия
MX2008014825A (es) 2006-05-22 2008-12-01 Hormos Medical Ltd Moduladores selectivos del receptor de estrogeno o inhibidores de aromatasa para tratar prostatitis cronica no bacteriana.
BRPI0711525A2 (pt) 2006-06-02 2011-11-01 Pear Tree Women S Health Care composição farmacêutica e método para tratar sintomas de vaginite atrófica
PL2121553T3 (pl) 2007-02-14 2012-11-30 Hormos Medical Ltd Sposób wytwarzania cennych terapeutycznie pochodnych trifenylobutenu
WO2008099060A2 (en) 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
AU2012204083C1 (en) * 2007-08-10 2015-02-05 Myriel Pharmaceuticals, Llc DHEA compositions for treating menopause
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20100075937A1 (en) * 2008-09-24 2010-03-25 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
RU2384894C1 (ru) * 2008-10-27 2010-03-20 Леонид Борисович Лазебник Способ моделирования остеопороза
CN102686600A (zh) * 2009-02-05 2012-09-19 托凯药业股份有限公司 甾体cyp17抑制剂/抗雄激素物质的新型药物前体
US20120142645A1 (en) * 2009-03-17 2012-06-07 Marx Christine E Neuroactive steroid compositions and methods of use for lowering cholesterol
AU2014201406B2 (en) * 2009-06-16 2016-08-11 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
RS56042B1 (sr) * 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
EA026675B1 (ru) 2010-06-16 2017-05-31 Эндорешерш, Инк. Способы лечения или предотвращения эстрогензависимых заболеваний
EP2635273B1 (en) 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoid compositions and methods for the treatment of cancer
WO2013006613A1 (en) 2011-07-05 2013-01-10 Novan, Inc. Methods of manufacturing topical compositions and apparatus for same
ES2804263T3 (es) * 2011-07-05 2021-02-05 Novan Inc Composiciones tópicas
WO2013012326A1 (en) * 2011-07-19 2013-01-24 Pantarhei Bioscience B.V. Tablet containing dehydroepiandrosterone (dhea)
US9320744B2 (en) 2011-10-19 2016-04-26 Dhea Llc DHEA bioadhesive controlled release gel
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
EP2791128A4 (en) 2011-12-16 2015-04-22 Olema Pharmaceuticals Inc NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF
CN102631677A (zh) * 2012-04-19 2012-08-15 中国农业大学 一种预防和/或治疗动脉粥样硬化的药物组合物
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
RU2015137617A (ru) 2013-03-14 2017-04-18 Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер Агенты, подавляющие андрогенные рецепторы, и их применение
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
US11813284B2 (en) 2013-08-08 2023-11-14 Novan, Inc. Topical compositions and methods of using the same
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
RU2545812C1 (ru) * 2014-02-24 2015-04-10 Аллан Герович Бениашвили Ородисперсная таблетка дегидроэпиандростерона
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
EP3166593B1 (en) 2014-07-11 2020-05-20 Novan, Inc. Topical antiviral compositions and methods of using the same
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
EP3177262A4 (en) 2014-08-08 2018-04-18 Novan Inc. Topical emulsions
GB201416186D0 (en) 2014-09-12 2014-10-29 Redx Pharma Ltd Compounds
CN116139125A (zh) 2015-02-02 2023-05-23 梅制药公司 联合治疗
US10452661B2 (en) * 2015-06-18 2019-10-22 Microsoft Technology Licensing, Llc Automated database schema annotation
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10912743B2 (en) 2016-03-02 2021-02-09 Novan, Inc. Compositions for treating inflammation and methods of treating the same
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US11166980B2 (en) 2016-04-13 2021-11-09 Novan, Inc. Compositions, systems, kits, and methods for treating an infection
FR3052805B1 (fr) 2016-06-20 2020-06-26 Safran Aircraft Engines Disque aubage monobloc ameliore, partie tournante d'une turbomachine comprenant un tel disque et turbomachine associee
CN109224029A (zh) * 2018-09-30 2019-01-18 泓博元生命科技（深圳）有限公司 含有nmn的降血脂组合物、制剂及其制备方法与应用
US12083130B2 (en) * 2019-10-03 2024-09-10 Caren Pharmaceuticals, Inc. Combination hormone formulations and therapies
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
EP4188552A2 (en) 2020-07-28 2023-06-07 Jazz Pharmaceuticals Ireland Limited Fused bicyclic raf inhibitors and methods for use thereof
JP2025506725A (ja) * 2022-02-17 2025-03-13 デブレツェン エジェテム Ｄｈｅａ由来ステロイド
CN115554403B (zh) * 2022-08-16 2024-03-08 山东大学 类固醇激素dhea作为受体adgrg2激动剂配体的应用

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US536220A (en) * 1895-03-26 Puzzle
US550107A (en) * 1895-11-19 Thirds to henry zervas and julius wegert
DK122125B (da) 1967-10-04 1972-01-24 Schering Ag Analogifremgangsmåde til fremstilling af terapeutisk aktive carboxylsyreestere af 3β-hydroxy-5-androstan-17-on(dehydroepiandrosteron) med 7-11 carbonatomer i esterresten.
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3797444A (en) 1971-04-19 1974-03-19 H Stubbs Towing guide
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4005200A (en) * 1975-07-17 1977-01-25 Kanebo, Ltd. Method for improving the maturity of the parturient canal and the sensitivity to oxytocin
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4496556A (en) 1982-08-16 1985-01-29 Norman Orentreich Topical applications for preventing dry skin
US4542129A (en) 1982-08-16 1985-09-17 Norman Orentreich DHEA Formulations and methods for treating dry skin
DE3333240A1 (de) 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4725439A (en) 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
IE58836B1 (en) 1984-08-02 1993-11-17 Labrie Fernand Pharmaceutical composition for combination therapy of hormone dependent cancers
US4624665A (en) 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4666441A (en) 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
IE60941B1 (en) 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
JP2551590B2 (ja) * 1987-06-26 1996-11-06 株式会社リコー 複写機光学系の速度制御方法
JPS6440428A (en) 1987-08-07 1989-02-10 Daiichi Yakuhin Sangyo Kk Antihyperlipemia
US5064654A (en) 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5162037A (en) 1988-04-01 1992-11-10 Whitson Laboratories, Inc. Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration
US5393785A (en) 1988-10-31 1995-02-28 Endorecherche, Inc. Therapeutic antiestrogens
US5686465A (en) 1988-10-31 1997-11-11 Endorecherche Inc. Sex steroid activity inhibitors
HU208150B (en) 1988-10-31 1993-08-30 Endorecherche Inc Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
CA2004203A1 (en) 1988-12-01 1990-06-01 Sharad K. Govil Compositions for transdermal delivery of estradiol
US4920115A (en) * 1988-12-28 1990-04-24 Virginia Commonwealth University Method of lowering LDL cholesterol in blood
ZA901847B (en) 1989-03-10 1991-10-30 Endorecherche Inc Combination therapy for the treatment of estrogen sensitive diseases
US5071644A (en) 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
ZA924811B (en) 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
HU222501B1 (hu) 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
HUT64815A (en) 1992-09-04 1994-03-28 Berki An external correcting and fixing apparatus for treatment of fractures and defomities of bones as well as correcting unit preferably for external correcting and fixing units
US5354861A (en) 1992-11-04 1994-10-11 National University Of Singapore 2-(benzyl)-3-arylbenzofurans as antitumour and hypocholesterolemic agents
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
SK286051B6 (sk) 1993-01-19 2008-02-05 Endorecherche Inc. Použitie prekurzora pohlavného steroidu na prípravu liečiva na prevenciu alebo liečenie znížených alebo nevyrovnaných koncentrácií pohlavných steroidov
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
DE4401554A1 (de) 1993-02-16 1994-08-18 Freund Andreas Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
DE69405491T2 (de) 1993-06-24 1998-02-19 Lilly Co Eli Antiöstrogene 2-Phenyl-3-Aroylbenzothiophene als hypoglykämische Mittel
US5482950A (en) 1993-10-15 1996-01-09 Eli Lilly And Company Methods for lowering serum cholesterol
US5391557A (en) 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome
US5441964A (en) 1993-10-15 1995-08-15 Eli Lilly And Company Methods for inhibiting bone loss using substituted benzothiophene
US5418252A (en) 1993-10-15 1995-05-23 Eli Lilly And Company Method for inhibiting cartilage degradation
US5407947A (en) 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5446061A (en) 1993-11-05 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
EP0654267B1 (en) * 1993-11-19 2002-04-10 Jenapharm GmbH & Co. KG Carcinostatic for hormonotheraphy containing dienogest as effective component
US5389646A (en) 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
US5591753A (en) * 1994-01-28 1997-01-07 Eli Lilly And Company Combination treatment for osteoporosis
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5425429A (en) * 1994-06-16 1995-06-20 Thompson; Michael C. Method and apparatus for forming lateral boreholes
US5681308A (en) 1994-06-24 1997-10-28 Stuart D. Edwards Ablation apparatus for cardiac chambers
PL181304B1 (pl) 1994-07-22 2001-07-31 Lilly Co Eli Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL
CZ52197A3 (en) 1994-08-22 1997-08-13 Lilly Co Eli Pharmaceutical preparation for treating teeth and mouth bone
TW404834B (en) 1994-08-22 2000-09-11 Lilly Co Eli Pharmaceutical compositions for inhibiting endometrial cancer
US5502074A (en) 1994-08-22 1996-03-26 Eli Lilly And Company Benzothiophenes for bone healing and fracture repair
US5550123A (en) 1994-08-22 1996-08-27 Eli Lilly And Company Methods for inhibiting bone prosthesis degeneration
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US6399634B1 (en) 1994-09-20 2002-06-04 Eli Lilly And Company Benzothiophene compounds, compositions, and methods
US6703407B1 (en) 1994-09-20 2004-03-09 Eli Lilly And Company Benzofuran compounds, compositions, and methods
US5637598A (en) 1994-11-18 1997-06-10 Eli Lilly And Company Methods of inhibiting bone loss
US5446071A (en) 1994-11-18 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
CN1167437A (zh) 1994-11-29 1997-12-10 赫彻斯特马里恩鲁斯公司 用三芳基-乙烯衍生物治疗和预防骨质疏松的方法
EP0804189A1 (en) * 1995-01-13 1997-11-05 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis or for anticoagulative treatment
US5489587A (en) 1995-01-20 1996-02-06 Eli Lilly And Company Benzofurans used to inhibit bone loss
US5571808A (en) 1995-01-31 1996-11-05 Eli Lilly And Company Method for treating smoking-related bone loss
US5552401A (en) 1995-02-28 1996-09-03 Eli Lilly And Company 2-benzyl-3-arylbenzothiophenes
US5523309A (en) 1995-03-10 1996-06-04 Eli Lilly And Company Benzofuran pharmaceutical compounds
DE69605600T2 (de) * 1995-06-06 2000-05-31 Eli Lilly And Co., Indianapolis Verringerung von Knochenschwund durch Antiöstrogen-Kombinationen
DE69600709T2 (de) 1995-06-07 1999-03-18 Eli Lilly And Co., Indianapolis, Ind. Verbindungen mit N-Acyliertem Piperidin in der Seitenkette und Zusammensetzungen
US5567828A (en) 1995-06-07 1996-10-22 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
WO1997025035A1 (en) 1996-01-11 1997-07-17 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
IL124881A0 (en) 1996-01-11 1999-01-26 Novo Nordisk As Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
JP2000505444A (ja) * 1996-02-14 2000-05-09 ヘキスト・マリオン・ルセル・インコーポレイテツド テストステロン５α―レダクターゼおよびＣ▲下１７―２０▼リアーゼの活性阻害剤としての１７β―シクロプロピル（アミノ／オキシ）４―アザステロイド
US6432982B1 (en) 1996-02-21 2002-08-13 Eli Lilly And Company Benzothiophenes, and formulations and methods using same
WO1997030709A1 (en) 1996-02-22 1997-08-28 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
IL120262A (en) 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
WO1997032837A1 (en) 1996-03-06 1997-09-12 Sumitomo Pharmaceuticals Co., Ltd. Nonsteroidal estrogen derivatives
EP0801066A1 (en) 1996-03-12 1997-10-15 Eli Lilly And Company Heterocyclic substituted benzothiophenes and pharmaceutical compositions
EP0925064B1 (en) * 1996-04-11 2003-06-25 LORIA, Roger M. 5-ANDROSTENE 3 beta,17alpha DIOL AS AN INHIBITOR OF TUMOR GROWTH
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
PT802183E (pt) 1996-04-19 2002-03-28 American Home Prod Agentes estrogenicos
US5843984A (en) 1996-05-09 1998-12-01 Eli Lilly And Company Sulfated benzothiophene derivatives, methods of use and formulations containing same
GB9616700D0 (en) * 1996-08-09 1996-09-25 Carey Beverly J Hormone supplement
BR9713176A (pt) * 1996-08-28 2000-02-08 Lilly Co Eli Benzotiofenos amorfos,métodos de preparação e métodos de uso
US6511970B1 (en) * 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US5861391A (en) * 1997-01-29 1999-01-19 Research Development Foundation Use of dehydroepiandrosterone to treat primary adrenal insufficiency and Addison's disease
AU6265998A (en) * 1997-02-07 1998-08-26 Theratech, Inc. Composition and method for supplementing testosterone in women with symptoms of testosterone deficiency
GB9708716D0 (en) * 1997-04-29 1997-06-18 Imperial College Chronic heart failure
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
CO4940467A1 (es) * 1997-06-27 2000-07-24 Smithkline Beecham Corp Nuevos metodos
US5908859A (en) * 1997-08-11 1999-06-01 Eli Lilly And Company Benzothiophenes for inhibiting hyperlipidemia
CA2306837C (en) * 1997-10-28 2007-05-08 Vivus, Inc. Treatment of female sexual dysfunction
EA005932B1 (ru) 1998-05-15 2005-08-25 Уайт 2-фенил-1-[4-(2-аминоэтокси)бензил]индол в комбинации с эстрогенами
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
MXPA00012304A (es) * 1998-06-11 2003-05-15 Endorech Inc Composiciones farmaceuticas y usos para el androst-5-ene-3beta, 17 beta-diol.
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
HUP9900284A2 (hu) 1999-02-09 2001-02-28 János Váradi Háromfázisú, hidraulikus rugózó elem közúti és vasúti járművek számára
CA2376158C (en) * 1999-07-06 2011-03-15 Endorecherche, Inc. Use of selective estrogen receptor modulators in the manufacture of medicaments for treating and/or suppressing weight gain
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
US8835413B2 (en) * 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions

Also Published As

Publication number Publication date
KR100944261B1 (ko) 2010-02-24
CA2768841C (en) 2013-08-13
US6670346B1 (en) 2003-12-30
MY157030A (en) 2016-04-15
CA2768773A1 (en) 1999-12-16
CA2632567A1 (en) 1999-12-16
EP2399582B9 (en) 2014-09-10
IL140178A (en) 2008-07-08
HK1040367B (zh) 2006-09-29
HK1040367A1 (en) 2002-06-07
PL203343B1 (pl) 2009-09-30
DK2386305T3 (da) 2014-04-14
EP1623712A3 (en) 2009-12-16
EP1623712B1 (en) 2012-12-12
ES2399051T3 (es) 2013-03-25
EP2386305B9 (en) 2014-12-17
WO1999063974A2 (en) 1999-12-16
AU4253099A (en) 1999-12-30
US7884092B2 (en) 2011-02-08
TR200100551T2 (tr) 2001-07-23
PT2399582E (pt) 2014-06-25
JP2007191484A (ja) 2007-08-02
CY1115069T1 (el) 2016-12-14
US7943603B2 (en) 2011-05-17
ZA200007297B (en) 2002-02-08
AR043075A1 (es) 2005-07-20
KR20090018871A (ko) 2009-02-23
MY151187A (en) 2014-04-30
US20070027124A1 (en) 2007-02-01
CA2334577A1 (en) 1999-12-16
NO20006254L (no) 2001-02-01
CA2768828C (en) 2013-08-13
ES2253922T3 (es) 2006-06-01
TWI258369B (en) 2006-07-21
HU1600307D0 (hu) 2002-02-28
TW200810763A (en) 2008-03-01
WO1999063974A3 (en) 2000-06-29
US7429576B2 (en) 2008-09-30
EP2386305A2 (en) 2011-11-16
EP2399582B1 (en) 2014-03-26
CY1115231T1 (el) 2017-01-04
EP1623712A2 (en) 2006-02-08
ES2458218T3 (es) 2014-04-30
ES2458218T9 (es) 2014-06-24
CN1636566A (zh) 2005-07-13
CA2768682A1 (en) 1999-12-16
NO20092730L (no) 2001-02-01
PT2386305E (pt) 2014-04-17
KR20090018227A (ko) 2009-02-19
CA2632567C (en) 2012-04-10
DK1623712T3 (da) 2013-01-21
MXPA00012306A (es) 2003-07-28
MY125047A (en) 2006-07-31
PL199798B1 (pl) 2008-10-31
US20070027123A1 (en) 2007-02-01
NO332187B1 (no) 2012-07-23
TR200103456T2 (tr) 2002-06-21
CA2334577C (en) 2008-08-05
JP2002517433A (ja) 2002-06-18
CA2768882C (en) 2015-01-27
NO331022B1 (no) 2011-09-12
CN1240388C (zh) 2006-02-08
KR20090018870A (ko) 2009-02-23
CA2768841A1 (en) 1999-12-16
TR200103453T2 (tr) 2002-06-21
ES2473040T3 (es) 2014-07-03
JP2013049703A (ja) 2013-03-14
EP2386305A3 (en) 2011-12-07
HUP0103345A2 (hu) 2002-02-28
KR20090018226A (ko) 2009-02-19
PT1623712E (pt) 2013-02-13
DK2399582T3 (da) 2014-07-07
NZ508801A (en) 2003-08-29
EP2386305B1 (en) 2014-02-12
EP2386304A2 (en) 2011-11-16
IL140178A0 (en) 2002-02-10
PL345887A1 (en) 2002-01-14
DE69928104D1 (de) 2005-12-08
RU2246947C2 (ru) 2005-02-27
CY1113712T1 (el) 2016-06-22
CA2768682C (en) 2014-03-18
CA2768828A1 (en) 1999-12-16
KR20090016771A (ko) 2009-02-17
HU230495B1 (hu) 2016-09-28
DK1083905T3 (da) 2006-03-20
US20070027122A1 (en) 2007-02-01
US8188066B2 (en) 2012-05-29
ES2463868T9 (es) 2014-06-24
PL195772B1 (pl) 2007-10-31
CA2768773C (en) 2013-08-13
CN1312718A (zh) 2001-09-12
TR200103455T2 (tr) 2002-06-21
EP2399582A1 (en) 2011-12-28
DE69928104T2 (de) 2006-08-24
CY1115317T1 (el) 2017-01-04
ATE308326T1 (de) 2005-11-15
US20040157812A1 (en) 2004-08-12
EP2386304B1 (en) 2014-03-19
CA2768882A1 (en) 1999-12-16
DK2386304T3 (da) 2014-05-12
ID28696A (id) 2001-06-28
HUP0103345A3 (en) 2002-11-28
ES2463868T3 (es) 2014-05-29
TWI371279B (en) 2012-09-01
IL185087A0 (en) 2007-12-03
EP2386304A3 (en) 2011-12-07
BR9911116A (pt) 2001-02-28
PL203704B1 (pl) 2009-11-30
US6465445B1 (en) 2002-10-15
EP1083905A2 (en) 2001-03-21
EP1083905B1 (en) 2005-11-02
EP2386304B9 (en) 2014-11-05
NO20006254D0 (no) 2000-12-08
PT2386304E (pt) 2014-05-26
KR20010052763A (ko) 2001-06-25

Similar Documents

Publication Publication Date Title
TR200103454T2 (tr) Cinsiyet steroidi öncüleri ile kombinasyon halindeki bir selektif östrojen reseptör modülatörünün tıbbi kullanımları.
HK1048761A1 (zh) 结合雌激素的选择性雌激素受体调节剂
ES2200384T3 (es) Medio anticonceptivo hormonal.
US20060009436A1 (en) 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
CA2050291A1 (en) Combination therapy for the treatment of estrogen sensitive diseases
Senaratne et al. The role of bisphosphonates in breast cancer: direct effects of bisphosphonates on breast cancer cells
PT94038B (pt) Processo para a preparacao de composicoes farmaceuticas que contem di-hidroespirorenona como antiandrogenio
BR9912466A (pt) Utilização de sulfamatos de estrogênio biogênicos na terapia de reposição hormonal
BRPI0617683A2 (pt) processo para a contracepção hormonal preventiva segundo a necessidade e uso de um emplastro transdérmico
JPH10147529A5 (tr)
Gordan et al. Calusterone (7β, 17α-DimethyItestosterone) as Primary and Secondary Therapy of Advanced Breast Cancer
TR199801915T2 (tr) Benzotiofenler, bunlari ihtiva eden formülasyonlar ve yöntemler.
AU2002215958C1 (en) Use of inhibitors of progesterone receptor for treating cancer
BR0213466A (pt) Uso de (11beta,17beta)-11-(1,3- benzodioxol-s-il)-17-hidróxi-17-(1-propinil) estra-4,9-dien-3-ona, preparação farmacêutica, e, método para o tratamento de um paciente sofrendo de distúrbio depressivo grave
EA201000097A1 (ru) 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов
WO1999045886A3 (en) New contraceptive kit for monotherapy
BR0016737A (pt) 14,15-ciclopropano-androstanos insaturados, processos para a sua preparação e composições farmacêuticas contendo estes compostos
WO2004093852A3 (en) Use of steroid derivatives for the treatment of angiotensin ii related disease e.g. cardiovascular and proliferative disorders
AU2006202187B2 (en) 17alpah-alkyl-17beta-oxy-estratrienes and intermediate products for their production, uses thereof and pharmaceutical preparations
BR9816142A (pt) Esteróides de 19-nor-colano como iniciadores neuroquìmicos de mudança na função hipotalâmica humana
ATE218366T1 (de) Pharmazeutische zusammensetzung enthaltend factor xiiia für nervenheilung
Rose Late sequelae of breast cancer treatment: systematic therapy
TR200200429T2 (tr) Kilo alımını tedavi ve/veya önleme metodları.
IE84077B1 (en) Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia